Benjamin Mullish

List of Publications by Year
in descending order

162	4,122	147801 31	133252 59
papers	citations	h-index	g-index

199	199	199	5429
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Non-selective beta-blocker use in cirrhosis: the additional benefit in preventing secondary infections. Frontline Gastroenterology, 2022, 13, flgastro-2021-101818.	1.8	1
2	Rapid resolution of COVID-19 after faecal microbiota transplantation. Gut, 2022, 71, 230-232.	12.1	44
3	The potential of fecal microbiota transplantation in oncology. Trends in Microbiology, 2022, 30, 10-12.	7.7	9
4	Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2022, 55, 26-48.	3.7	23
5	How to adapt an intestinal microbiota transplantation programme to reduce the risk of invasive multidrug-resistant infection. Clinical Microbiology and Infection, 2022, 28, 502-512.	6.0	6
6	The Intestinal Barrier and Its Dysfunction in Patients with Metabolic Diseases and Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2022, 23, 662.	4.1	17
7	The potential utility of fecal (or intestinal) microbiota transplantation in controlling infectious diseases. Gut Microbes, 2022, 14, 2038856.	9.8	16
8	Effects of bowel preparation on intestinal bacterial associated urine and faecal metabolites and the associated faecal microbiome. BMC Gastroenterology, 2022, 22, 240.	2.0	11
9	Further Insights Into the Impact of Bariatric Surgery on the Progression of Nonalcoholic Fatty Liver Disease. Gastroenterology, 2022, 163, 528-529.	1.3	1
10	Intestinal microbiota transplantation: do not forget the metabolites. The Lancet Gastroenterology and Hepatology, 2022, 7, 594.	8.1	4
11	Inflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent C. difficile Infection. Inflammatory Bowel Diseases, 2021, 27, 1371-1378.	1.9	31
12	Identifying the factors influencing outcome in probiotic studies in overweight and obese patients: host or microbiome?. Gut, 2021, 70, 225-226.	12.1	6
13	Disease Prevention Not Decolonization: A Model for Fecal Microbiota Transplantation in Patients Colonized With Multidrug-resistant Organisms. Clinical Infectious Diseases, 2021, 72, 1444-1447.	5.8	40
14	NAFLD: Time to apply quantitation in liver biopsies as endpoints in clinical trials. Journal of Hepatology, 2021, 74, 241-242.	3.7	7
15	Probiotics reduce self-reported symptoms of upper respiratory tract infection in overweight and obese adults: should we be considering probiotics during viral pandemics?. Gut Microbes, 2021, 13, 1-9.	9.8	28
16	The contribution of bile acid metabolism to the pathogenesis of Clostridioides difficile infection. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110177.	3.2	24
17	P307â€…FMT-associated alterations in the TCR repertoire of patients with severe or fulminant clostridioides difficile infection. , 2021, , .		0
18	Daily supplementation with the Lab4P probiotic consortium induces significant weight loss in overweight adults. Scientific Reports, 2021, 11, 5.	3.3	18

#	Article	IF	Citations
19	Fecal Microbiota Transplantation: The Evolving Risk Landscape. American Journal of Gastroenterology, 2021, 116, 647-656.	0.4	37
20	Romanian National Guideline on Translating Fecal Microbiota Transplantation Applications related to Clostridioides difficile Infections into the Local Clinical Practice. Journal of Gastrointestinal and Liver Diseases, 2021, 30, 147-163.	0.9	0
21	SARS-CoV-2 vaccines and donor recruitment for FMT. The Lancet Gastroenterology and Hepatology, 2021, 6, 264-266.	8.1	5
22	739 DAILY PROBIOTIC USE IS ASSOCIATED WITH A REDUCED RATE OF UPPER RESPIRATORY TRACT SYMPTOMS IN OVERWEIGHT AND OBESE PEOPLE. Gastroenterology, 2021, 160, S-150.	1.3	0
23	Sa022 A HIGH-FIBER LOW-FAT DIET INCREASES FECAL LEVELS OF LITHOCHOLIC ACID DERIVATIVE 3-KETOCHOLANIC ACID. Gastroenterology, 2021, 160, S-393-S-394.	1.3	0
24	Fr571 A DISTINCTIVE SIGNATURE OF FECAL BILE ACIDS AND OTHER NOVEL METABOLITES ACCOMPANYING RECURRENCE AFTER PRIMARY CLOSTRIDIOIDES DIFFICILE INFECTION. Gastroenterology, 2021, 160, S-368.	1.3	0
25	811 FECAL MICROBIOTA TRANSPLANT PRIOR TO ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT IN PATIENTS COLONIZED WITH MULTI-DRUG RESISTANT ORGANISMS IS ASSOCIATED WITH IMPROVED SURVIVAL. Gastroenterology, 2021, 160, S-168-S-169.	1.3	0
26	Fr573 ASSOCIATION BETWEEN NOVEL METABOLOMIC BIOMARKERS AND C.DIFFICILE RECURRENCE. Gastroenterology, 2021, 160, S-369.	1.3	0
27	Su541 RECTAL SWABS AS A VIABLE ALTERNATIVE TO FECAL SAMPLING FOR THE ANALYSIS OF GUT MICROBIOME FUNCTIONALITY AS WELL AS COMPOSITION. Gastroenterology, 2021, 160, S-733.	1.3	0
28	Bingeâ€eating disorder is associated with an unfavorable body mass composition in patients with nonâ€alcoholic fatty liver disease. International Journal of Eating Disorders, 2021, 54, 2025-2030.	4.0	5
29	Multiomics Profiling Reveals Signatures of Dysmetabolism in Urban Populations in Central India. Microorganisms, 2021, 9, 1485.	3.6	3
30	The use of Faecal Microbiota Transplantation (FMT) in Europe: A Europe-wide survey. Lancet Regional Health - Europe, The, 2021, 9, 100181.	5.6	43
31	Fecal Microbiota Transplant Mitigates Adverse Outcomes Seen in Patients Colonized With Multidrug-Resistant Organisms Undergoing Allogeneic Hematopoietic Cell Transplantation. Frontiers in Cellular and Infection Microbiology, 2021, 11, 684659.	3.9	14
32	Fecal microbiota transplantation with ruxolitinib as a treatment modality for steroidâ€refractory/dependent acute, gastrointestinal graftâ€versusâ€host disease: A case series. American Journal of Hematology, 2021, 96, E461-E463.	4.1	10
33	Impact of fecal microbiota transplantation with capsules on the prevention of metabolic syndrome among patients with obesity. Hormones, 2021, 20, 209-211.	1.9	24
34	Changes in IgA-targeted microbiota following fecal transplantation for recurrent Clostridioides difficile infection. Gut Microbes, 2021, 13, 1-12.	9.8	10
35	Reply to Woodworth, et al.. Clinical Infectious Diseases, 2021, 72, e924-e925.	5.8	1
36	The gut microbiome: what every gastroenterologist needs to know. Frontline Gastroenterology, 2021, 12, 118-127.	1.8	16

#	Article	IF	Citations
37	A Multi-Factorial Observational Study on Sequential Fecal Microbiota Transplant in Patients with Medically Refractory Clostridioides difficile Infection. Cells, 2021, 10, 3234.	4.1	14
38	Impact of gastrointestinal surgery upon the gut microbiome: AÂsystematic review. Surgery, 2021, , .	1.9	6
39	Clostridioides difficile: innovations in target discovery and potential for therapeutic success. Expert Opinion on Therapeutic Targets, 2021, , 1-15.	3.4	5
40	Liver function tests and metabolic-associated fatty liver disease: Changes in upper normal limits, does it really matter?. World Journal of Hepatology, 2021, 13, 2104-2112.	2.0	6
41	In search of stool donors: a multicenter study of prior knowledge, perceptions, motivators, and deterrents among potential donors for fecal microbiota transplantation. Gut Microbes, 2020, 11, 51-62.	9.8	22
42	Recurrent bacteraemia following variceal haemorrhage. Gut, 2020, 69, 726-780.	12.1	0
43	Effects of Fecal Microbiota Transplantation With Oral Capsules in Obese Patients. Clinical Gastroenterology and Hepatology, 2020, 18, 855-863.e2.	4.4	171
44	Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms. Immunology, 2020, 159, 167-177.	4.4	75
45	High-Throughput, Machine Learningâ€“Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2020, 18, 2081-2090.e9.	4.4	85
46	In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19. PLoS ONE, 2020, 15, e0240400.	2.5	54
47	P844 Higher proportions of genera and species in the Firmicutes phylum are associated with a healthy pouch compared with patients with chronic pouchitis. Journal of Crohn's and Colitis, 2020, 14, S652-S652.	1.3	0
48	Letter: faecal microbiota transplantation for IBS. Alimentary Pharmacology and Therapeutics, 2020, 52, 556-557.	3.7	8
49	Letter: liver disease and COVID-19-not the perfect storm. Alimentary Pharmacology and Therapeutics, 2020, 52, 572-574.	3.7	3
50	644 IDENTIFICATION OF NOVEL CHANGES IN MICROBIALLY-DERIVED METABOLITES AFTER FECAL MICROBIOTA TRANSPLANT FOR RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION. Gastroenterology, 2020, 158, S-138-S-139.	1.3	0
51	Tu1909 IMPACT OF FECAL MICROBIOTA TRANSPLANTATION ON PREVENTION OF METABOLIC SYNDROME AMONG PATIENTS WITH OBESITY. Gastroenterology, 2020, 158, S-1214-S-1215.	1.3	1
52	The gut microbiome: an under-recognised contributor to the COVID-19 pandemic?. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482097491.	3.2	50
53	1144 FECAL MICROBIOTA TRANSPLANT FOR MULTI-DRUG RESISTANT ORGANISMS: IMPROVED CLINICAL OUTCOMES BEYOND INTESTINAL DECOLONISATION. Gastroenterology, 2020, 158, S-227-S-228.	1.3	1
54	Mo1939 TEMPORAL MODULATION OF TCR REPERTOIRE FOLLOWING SEQUENTIAL FMT TREATMENT IN PATIENTS WITH SEVERE OR FULMINANT CLOSTRIDIOIDES DIFFICILE INFECTION. Gastroenterology, 2020, 158, S-985-S-986.	1.3	0

#	Article	IF	Citations
55	Outcomes of Fecal Microbiota Transplantation in Patients With Inflammatory Bowel Diseases and Recurrent Clostridioides difficile Infection. Gastroenterology, 2020, 159, 1982-1984.	1.3	28
56	121 ULCERATIVE COLITIS PATIENTS ACHEIVE MORE ROBUST ENGRAFTMENT COMPARED TO PATIENTS WITH CROHN'S DISEASE AFTER FECAL MICROBIOTA TRANSPLANTATION FOR THE TREATMENT OF RECURRENT C. DIFFICILE INFECTION. Gastroenterology, 2020, 158, S-22.	1.3	1
57	A Guide to the Gut Microbiome and its Relevance to Critical Care. British Journal of Nursing, 2020, 29, 1106-1112.	0.7	0
58	Mechanisms underpinning the efficacy of faecal microbiota transplantation in treating gastrointestinal disease. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482094690.	3.2	21
59	Fecal microbiota transplantation in gastrointestinal and extraintestinal disorders. Future Microbiology, 2020, 15, 1173-1183.	2.0	18
60	Results of the PROFIT trial, a PROspective randomised placebo-controlled feasibility trial of Faecal mIcrobiota Transplantation in advanced cirrhosis. Journal of Hepatology, 2020, 73, S77-S78.	3.7	3
61	Understanding the mechanisms of efficacy of fecal microbiota transplant in treating recurrent Clostridioides difficile infection and beyond: the contribution of gut microbial-derived metabolites. Gut Microbes, 2020, 12, 1810531.	9.8	32
62	Faecal microbiota transplantation for recurrent Clostridioides difficile infection: An updated systematic review and meta-analysis. EClinicalMedicine, 2020, 29-30, 100642.	7.1	111
63	A Two-Way Interaction between Methotrexate and the Gut Microbiota of Male Sprague–Dawley Rats. Journal of Proteome Research, 2020, 19, 3326-3339.	3.7	35
64	Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel. The Lancet Gastroenterology and Hepatology, 2020, 5, 430-432.	8.1	108
65	A randomised controlled study shows supplementation of overweight and obese adults with lactobacilli and bifidobacteria reduces bodyweight and improves well-being. Scientific Reports, 2020, 10, 4183.	3.3	56
66	Ursodeoxycholic acid enriches intestinal bile salt hydrolase-expressing Bacteroidetes in cholestatic pregnancy. Scientific Reports, 2020, 10, 3895.	3.3	27
67	Intestinal microbiome transfer, a novel therapeutic strategy for COVID-19 induced hyperinflammation?. Clinical Immunology, 2020, 218, 108542.	3.2	12
68	Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic. Gut, 2020, 69, 1555-1563.	12.1	110
69	Faecal microbiota transplantations and urinary tract infections –" Authors' reply. Lancet, The, 2020, 395, 271.	13.7	2
70	Letter: intestinal microbiota transfer–"updating the nomenclature to increase acceptability. Alimentary Pharmacology and Therapeutics, 2020, 52, 1622-1623.	3.7	3
71	Non-Alcoholic Fatty Liver Disease and Vascular Disease. Current Vascular Pharmacology, 2020, 19, 269-279.	1.7	12
72	Case-control study of recurrent Extended-Spectrum Beta Lactamase Enterobacteriaceae Urinary Tract Infections (ESBL UTIs): the management challenges. Access Microbiology, 2020, 2, .	0.5	0

#	Article	IF	Citations
73	Sa1923 IDENTIFICATION OF NEW ASSOCIATIONS BETWEEN PSORIATIC ARTHRITIS AND THE GUT MICROBIOTA, A PHENOMIC STUDY. Gastroenterology, 2020, 158, S-481.	1.3	0
74	Cohort study of Faecal Microbiota Transplantation for patientâ€™s colonised with MDROs - successful prevention of invasive disease despite low decolonisation rates. Access Microbiology, 2020, 2, .	0.5	0
75	S0650â€ƒFecal Microbiota Transplantation Decolonizes C. difficile in Patients With Inflammatory Bowel Disease and Concomitant C. difficile Infection. American Journal of Gastroenterology, 2020, 115, S326-S326.	0.4	0
76	The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications. Lancet, The, 2019, 394, 420-431.	13.7	234
77	PS-174-Serum bile acid profiles distinguish severe alcoholic hepatitis from decompensated alcohol-related cirrhosis. Journal of Hepatology, 2019, 70, e108.	3.7	1
78	THU-306-Liver function tests in NAFLD: Changes in upper normal limits, does it really matter?. Journal of Hepatology, 2019, 70, e295.	3.7	0
79	THU-331-Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non-alcoholic fatty liver disease: The importance of an elevated mean platelet volume. Journal of Hepatology, 2019, 70, e305.	3.7	0
80	Antibiotic therapy and outcome from immune-checkpoint inhibitors. , 2019, 7, 287.		77
81	Posters (Abstracts 289â€“2348). Hepatology, 2019, 70, 188-1382.	7.3	17
82	Letter: role of mean platelet volume levels in the prediction of major acute cardiovascular events in patients with nonâ€alcoholic fatty liver diseaseâ€”authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 50, 1140-1141.	3.7	0
83	Mo1953 â€“ Growth Inhibition of Clostridioides Difficile by Short and Medium Chain Fatty Acids. Gastroenterology, 2019, 156, S-898.	1.3	0
84	7 â€“ The Icon Study: Inflammatory Bowel Disease and Recurrent Clostridium Difficile Infection: Outcomes After Fecal Microbiota Transplantation. Gastroenterology, 2019, 156, S-2-S-3.	1.3	3
85	The application of omics techniques to understand the role of the gut microbiota in inflammatory bowel disease. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481882225.	3.2	49
86	Faecal microbiota transplant for eradication of multidrug-resistant Enterobacteriaceae: a lesson in applying best practice? Re: â€˜A five-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant Enterobacteriaceae: A Randomized Clinical Trialâ€™. Clinical Microbiology and Infection, 2019, 25, 912-913.	6.0	3
87	Editorial: importance of an elevated mean platelet volume for prediction of major adverse cardiovascular events in nonâ€alcoholic fatty liver disease â€“ authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2019, 49, 1093-1094.	3.7	2
88	Current and future pharmacological therapies for managing cirrhosis and its complications. World Journal of Gastroenterology, 2019, 25, 888-908.	3.3	36
89	621 â€“ Fecal Microbiota Transplantation for the Treatment of Obesity: A Randomized, Placebo-Controlled Pilot Trial. Gastroenterology, 2019, 156, S-129.	1.3	1
90	Sa1924 â€“ Effect of Short Chain Fatty Acids on Gut-Brain Axis Using a Microglial Cell Model. Gastroenterology, 2019, 156, S-455.	1.3	2

#	Article	IF	Citations
91	SAT-294-Automated quantitation of steatosis, inflammation, ballooning and fibrosis using machine learning in routine histological images of liver biopsies of patients with NAFLD. Journal of Hepatology, 2019, 70, e767-e768.	3.7	0
92	Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in nonâ€alcoholic fatty liver disease; the importance of an elevated mean platelet volume. Alimentary Pharmacology and Therapeutics, 2019, 49, 1077-1085.	3.7	35
93	Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: A Pilot Clinical Trial. American Journal of Gastroenterology, 2019, 114, 1071-1079.	0.4	155
94	Autotaxin, bile acid profile and effect of ileal bile acid transporter inhibition in primary biliary cholangitis patients with pruritus. Liver International, 2019, 39, 967-975.	3.9	22
95	Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent Clostridioides difficile infection. Gut, 2019, 68, 1791-1800.	12.1	182
96	837â€ƒShort Chain Fatty Acid Profiles Are Altered by Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease and Recurrent Clostridioides difficile Infection. American Journal of Gastroenterology, 2019, 114, S484-S485.	0.4	0
97	Gaps in knowledge and future directions for the use of faecal microbiota transplant in the treatment of inflammatory bowel disease. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481989103.	3.2	15
98	185â€ƒEvaluating Dynamics of Bile Acid Metabolism to Predict Recurrence of Clostridioides difficile Infection. American Journal of Gastroenterology, 2019, 114, S113-S113.	0.4	1
99	International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. Gut, 2019, 68, 2111-2121.	12.1	290
100	Effective fecal microbiota transplantation for recurrent Clostridioides difficile infection in humans is associated with increased signalling in the bile acid-farnesoid X receptor-fibroblast growth factor pathway. Gut Microbes, 2019, 10, 142-148.	9.8	44
101	Current and future targets for faecal microbiota transplantation. Human Microbiome Journal, 2019, 11, 100045.	3.8	7
102	MP71-15â€ƒPREVALENCE OF RECURRENT EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) URINARY TRACT INFECTIONS (UTIS) IN PATIENTS WITHIN A UROLOGY SERVICE. INTRODUCING THE CONCEPT OF FAECAL MICROBIOTA TRANSPLANTATION (FMT) AS A TREATMENT MODALITY. Journal of Urology, 2019, 201, .	0.4	0
103	Gastrointestinal: Duodenal variceal bleeding secondary to thrombophiliaâ€related portal vein thrombosis. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 336-336.	2.8	0
104	Functional microbiomics: Evaluation of gut microbiota-bile acid metabolism interactions in health and disease. Methods, 2018, 149, 49-58.	3.8	76
105	Meeting update: faecal microbiota transplantationâ€“â€“bench, bedside, courtroom?. Frontline Gastroenterology, 2018, 9, 45-48.	1.8	4
106	1171. Impact on Mortality, Length of Stay, and Antibiotic Use in Allogenic and Autologous Stem Cell Transplant Patients Colonized With Carbapenemase-Producing Enterobacteriaceae. Open Forum Infectious Diseases, 2018, 5, S353-S354.	0.9	0
107	PWE-052â€…Long term outcomes of initial IFX therapy for inflammatory pouch pathology: a multi-centre retrospective study. , 2018, , .		1
108	IDDF2018-ABS-0056â€…Long term outcomes of initial infliximab therapy for inflammatory pouch pathology: a multi-centre retrospective study. , 2018, , .		0

#	Article	IF	Citations
109	Non-alcoholic fatty liver disease and cardiovascular risk: an update. Expert Review of Gastroenterology and Hepatology, 2018, 12, 1175-1177.	3.0	10
110	Inhibiting Growth of Clostridioides difficile by Restoring Valerate, Produced by the Intestinal Microbiota. Gastroenterology, 2018, 155, 1495-1507.e15.	1.3	127
111	The implementation of omics technologies in cancer microbiome research. Ecancermedicalscience, 2018, 12, 864.	1.1	13
112	Introduction to the joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) faecal microbiota transplant guidelines. Journal of Hospital Infection, 2018, 100, 130-132.	2.9	14
113	Long term outcomes of initial infliximab therapy for inflammatory pouch pathology: a multi-Centre retrospective study. Scandinavian Journal of Gastroenterology, 2018, 53, 1051-1058.	1.5	12
114	Fecal microbiota and bile acid interactions with systemic and adipose tissue metabolism in diet-induced weight loss of obese postmenopausal women. Journal of Translational Medicine, 2018, 16, 244.	4.4	78
115	The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Journal of Hospital Infection, 2018, 100, S1-S31.	2.9	38
116	Antibioticâ€Associated Disruption of Microbiota Composition and Function in Cirrhosis Is Restored by Fecal Transplant. Hepatology, 2018, 68, 1205-1205.	7.3	6
117	24 - A Novel Route to Controlling Clostridioides Difficile Growth via Short Chain Fatty Acid and Bile Acid Modulation. Gastroenterology, 2018, 154, S-8.	1.3	0
118	25 - Microbiome and Metabolic Markers of Clostridium Difficile Recurrance. Gastroenterology, 2018, 154, S-8-S-9.	1.3	2
119	A mobile application for the management and follow-up of patients with Non-Alcoholic Fatty Liver Disease. Journal of Hepatology, 2018, 68, S819.	3.7	0
120	The use of faecal microbiota transplant as treatment for recurrent or refractoryClostridium difficileinfection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut, 2018, 67, 1920-1941.	12.1	248
121	Clostridium difficile infection and antibiotic-associated diarrhoea. Clinical Medicine, 2018, 18, 237-241.	1.9	114
122	Tu1894 - Potential Motivators and Deterents for Stool Donors: A Multicenter Study. Gastroenterology, 2018, 154, S-1051.	1.3	0
123	Letter: improvements in mental health after faecal microbiota transplantationâ€"an underexplored treatmentâ€related benefit?. Alimentary Pharmacology and Therapeutics, 2018, 47, 1562-1563.	3.7	3
124	Bile Acid Profiles are Not Altered by Fecal Microbiota Transplantation for the Treatment of Primary Sclerosing Cholangitis: Category Award (Liver): Presidential Poster Award. American Journal of Gastroenterology, 2018, 113, S574-S576.	0.4	2
125	Anticoagulation in chronic liver disease. Journal of Hepatology, 2017, 66, 1313-1326.	3.7	45
126	Understanding the Mechanisms of Efficacy of Fecal Microbiota Transplantation in the Treatment of Clostridium Difficile Infection: The Potential Role of Bilemetabolising Enzymes. Gastroenterology, 2017, 152, S47.	1.3	2

#	Article	IF	Citations
127	Comparative epidemiology of Clostridium difficile infection: England and the USA. International Journal for Quality in Health Care, 2017, 29, 785-791.	1.8	16
128	Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. Hepatology, 2017, 66, 1354-1355.	7.3	25
129	Faecal microbiota transplant: a novel biological approach to extensively drug-resistant organism-related non-relapse mortality. Bone Marrow Transplantation, 2017, 52, 1452-1454.	2.4	27
130	The severity of steatosis does not influence liver stiffness measurements in patients with Non-Alcoholic Fatty Liver Disease. Journal of Hepatology, 2017, 66, S586-S587.	3.7	0
131	PWE-093â€...Development and validation of an automated system for assessment of liver steatosis and fibrosis in routine: histological images in patients with non-alcoholic fatty liver disease. , 2017, , .		0
132	National survey of practice of faecal microbiota transplantation for Clostridium difficile infection in the UK. Journal of Hospital Infection, 2017, 95, 444-445.	2.9	20
133	PWE-094â€...The severity of steatosis does not influence liver stiffness measurements in patients with non-alcoholic fatty liver disease. , 2017, , .		0
134	OC-040â€...National Survey of Practice of Faecal Microbiota Transplantation for Clostridium Difficile Infection in the United Kingdom. Gut, 2016, 65, A23.2-A24.	12.1	0
135	PWE-094â€...Understanding The Efficacy of Faecal Microbiota Transplantation in Clostridium Difficile Infection: Re-Establishment of Gut Microbiota with The Ability to Degrade Bile?. Gut, 2016, 65, A184.2-A184.	12.1	0
136	Optimized Sample Handling Strategy for Metabolic Profiling of Human Feces. Analytical Chemistry, 2016, 88, 4661-4668.	6.5	134
137	Global Metabolic Stress of Isoeffort Continuous and High Intensity Interval Aerobic Exercise: A Comparative ¹H NMR Metabonomic Study. Journal of Proteome Research, 2016, 15, 4452-4463.	3.7	33
138	Obstacles to establishing an NHS faecal transplant programme. BMJ, The, 2015, 351, h6043-h6043.	6.0	8
139	Weight loss in a man from West Africa. Gut, 2015, 64, 1846-1846.	12.1	3
140	Letter: depression and the use of antiâ€depressants in patients with chronic liver disease or liver transplantation â€“ authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2015, 41, 914-915.	3.7	1
141	Monitoring the Response of the Human Urinary Metabolome to Brief Maximal Exercise by a Combination of RP-UPLC-MS and ¹H NMR Spectroscopy. Journal of Proteome Research, 2015, 14, 4610-4622.	3.7	46
142	Bile Acid Profiling and Quantification in Biofluids Using Ultra-Performance Liquid Chromatography Tandem Mass Spectrometry. Analytical Chemistry, 2015, 87, 9662-9670.	6.5	166
143	Microbiome manipulation with faecal microbiome transplantation as a therapeutic strategy in Clostridium difficile infection. QJM - Monthly Journal of the Association of Physicians, 2015, 108, 355-359.	0.5	13
144	Aspartame Sensitivity? A Double Blind Randomised Crossover Study. PLoS ONE, 2015, 10, e0116212.	2.5	11

#	Article	IF	Citations
145	Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation. Alimentary Pharmacology and Therapeutics, 2014, 40, 880-892.	3.7	100
146	Case 25-2014: A Man with Ulcerative Colitis and Bloody Diarrhea. New England Journal of Medicine, 2014, 371, 1848-1849.	27.0	5
147	Severe cholestatic jaundice after a single administration of ajmaline; a case report and review of the literature. BMC Gastroenterology, 2014, 14, 60.	2.0	6
148	P306 MONOCYTE OXIDATIVE BURST DEFECT PREDICTS RISK OF INFECTION IN ALCOHOLIC HEPATITIS. Journal of Hepatology, 2014, 60, S168.	3.7	0
149	Low Incidence Of Venous Thromboembolism In Mobile Populations. Value in Health, 2014, 17, A152.	0.3	0
150	Shoulder pain and dysphagia with an unexpected cause. BMJ Case Reports, 2011, 2011, bcr0720103176-bcr0720103176.	0.5	1
151	Renal medicine. , 0, , 251-251.		0
152	Haematology and oncology. , 0, , 159-159.		0
153	Clinical sciences. , 0, , 59-59.		0
154	Respiratory medicine. , 0, , 283-283.		0
155	Clinical pharmacology, therapeutics and toxicology. , 0, , 25-25.		0
156	Tropical, infectious and sexually transmitted diseases. , 0, , 345-345.		0
157	Infectious diseases and GUM. , 0, , 211-211.		0
158	Clinical haematology and oncology. , 0, , 27-27.		0
159	Clinical sciences. , 0, , 95-95.		0
160	Respiratory medicine. , 0, , 329-329.		0
161	Review of Rifaximin: A Summary of the Current Evidence and Benefits Beyond Licensed Use. European Medical Journal (Chelmsford, England), 0, , 94-100.	3.0	0
162	Outcomes of postmenopausal women with non-alcoholic fatty liver disease (NAFLD). Endocrine Abstracts, 0, , .	0.0	0